Artificial Blood Vessels Market Size Analysis

The Artificial Blood Vessels Market size was valued at USD 2.26 billion in 2024 and is expected to reach USD 3.43 billion by 2032, growing at a CAGR of 5.38% over 2025-2032.

The global artificial blood vessels market is gaining momentum on account of the rising prevalence of cardiovascular disease (CVD), the rising geriatric population, and the pressing need for suitable vascular grafts. In high-incidence areas, the need for artificial blood vessels has increased 5–10-fold along with the increase in the number of patients with atherosclerosis and peripheral artery disease.

The increasing use of coronary artery bypass graft (CABG) surgery, performing more than 400,000 of these procedures in the U.S. alone every year, illustrates the urgent necessity for biocompatible and durable synthetic grafts. Moreover, growing penetration of hybrid operating rooms in cardiac centers and hospitals such as UCSF and Brigham and Women’s Hospital has provided impetus to complex vascular interventions, fueling the U.S. artificial blood vessels market.

For instance, A first-in-human clinical scenario was approved by the FDA recently for a tissue-engineered blood vessel based on the decellularized human vessels; it implies favorable regulatory pathways, and it is also aiding the artificial blood vessels market in terms of opportunities on the innovation side.

The regulatory momentum for continued innovation was witnessed in the automatic process of fast-track designation by the FDA of TVEs and the growth in the R&D investment from NIH and EU Horizon grants. Upstart artificial blood vessel ventures are gravitating more and more toward nanofiber scaffolds and 3D bioprinting approaches buoyed by encouraging preclinical studies from the pages of Science and Nature Biomedical Engineering. Furthermore, strategic partnerships like that between academic institutes and med-tech giants are improving the scalability and commercialization and contributing to the artificial blood vessels market expansion. Also, supply-side help that has contributed is the scaling up of manufacturing and higher investment in the development of biocompatible polymers.

In 2024, a group of researchers at the University of Sydney and Harvard developed a 3D-printed blood vessel scaffold designed using the biomimetic approach and demonstrated effective results, with clinical possibilities in preclinical models, thereby fueling the artificial blood vessels market growth.

Artificial Blood Vessels Market Dynamics

Drivers:

• Rising Demand for Bioengineered Solutions and Surgical Advancements Propel Market Growth

Growing demand for bioengineered vascular grafts, especially when the autologous veins are not available, which has been the case with repeated CABG procedures or peripheral artery disease, is expected to drive the artificial blood vessels market. More than 20% of conventional bypass surgeries fail because of the lack of a suitable graft or because the graft compatibility is too low, causing a change of focus toward synthetic and tissue-engineered grafts. Investment in artificial blood vessels companies is also growing, with biotech and med-tech startups receiving multimillion-dollar investments and venture capital crops.

For instance, Humacyte’s USD 255 million financing in human acellular vessels (HAVs). In addition, U.S. FDA Breakthrough Device status for bioengineered vessels in end-stage renal disease and critical limb ischemia signals regulatory support. Biomimetic scaffolds are increasingly used by surgeons for their lower thrombogenicity and good integration. Supply-side, companies are ramping up production of nanofibers and decellularized tissue to keep pace with burgeoning hospital and research demand. NIH statistics show cardiovascular R&D represented more than USD 2.4 billion in 2023, detailing efforts in vascular materials and regenerative therapies. These, along with positive clinical outcomes and increased adoption by the cardiothoracic surgeons, are driving the market growth of artificial blood vessels and their growing applications to trauma care, dialysis, and congenital vascular malformations.

Restraints:

• Biocompatibility Limitations and Long-Term Efficacy Concerns Impede Market Expansion

Challenges for the artificial blood vessels market include the immune reaction as well as the risks of thrombosis and limited long-term use of the grafts, especially for small diameters (<6 mm), which may have failure rates of as much as 50% within 2 years. Some of the previously developed synthetic materials, for instance, expanded polytetrafluoroethylene (ePTFE), have a limited patency in arterial replacements of a certain diameter, and, therefore, are limited in application. Furthermore, novel grafts are frequently delayed in clinical trials due to regulatory difficulty and demand for rigorous evidence of biocompatibility, even under fast-track situations, FDA clearances/approvals can take 3–5 years. Manufacturing scalability is also challenging; biofabrication technologies such as electrospinning and 3D bioprinting are still labor-intensive and expensive.

Supply chain problems around raw biomaterials, including collagen and elastin, are adding to the production bottleneck. And there are issues after surgery, such as infections, abnormal tissue growth, and mismatched materials, that make it difficult for these visits to gain widespread adoption in hospitals. Clinical trials have been published in Circulation Research and Journal of Vascular Surgery, but results appear variable among the patient populations, which has hindered reimbursement approvals from health systems. These aspects together affect the artificial blood vessels industry share and hinder the translation from laboratory to bedside.

Artificial Blood Vessels Market Segmentation Analysis

By Polymer Type

Polyethylene terephthalate (PET) held a dominant position in the artificial blood vessels market with a share of more than 40% in the market in 2024. Such superiority is associated with PET’s excellent mechanical property, strong stability, as well as its good hemocompatibility, which is good enough for the application in large diameter vessel replacement, such as the aorta. Its broad clinical acceptance, its long history of safe use, and its compatibility with modern textile-processing technologies contribute to its market dominance. Polydioxanone section, on the other hand, is projected to witness as fastest growth owing to its biodegradable nature, low level of inflammatory response, and growing adoption for temporary vascular scaffolds. Its resorbable characteristics have made it particularly attractive for use in pediatric and reconstructive vascular procedures, where the goal of vessel regeneration is to occur naturally.

By Application

Aortic disease dominated the market in 2024 and accounted for more than 45% of the market in the artificial blood vessels market. This is due mainly to the high global prevalence of aortic aneurysms and dissections for which synthetic grafts are necessary for open and endovascular repair. The leading position of this segment has been further fortified with the use of PET grafts and with the introduction of FDA-approved products. In the meantime, the hemodialysis segment is expected to expand at the fastest CAGR owing to the increasing incidence of end-stage renal disease (ESRD). With more than 2,000,000 dialysis patients worldwide and the fact that vascular access miseries are the leading cause of hospitalization, the requirements for bioengineered grafts in dialysis access surgery are escalating.

By End-users

Hospitals led the market in 2024, holding more than 54% of the share of the artificial blood vessels market. This is likely due to the heavy high-risk cardiovascular procedure load, the existence of hybrid operating rooms, and experienced surgical teams. Hospitals are the core site for aortic repairs, trauma aid, and complex bypass operations in need of artificial vascular grafts. Utilization of ASCs is projected to grow at a faster rate. This demand is driven by more minimally invasive vascular procedures moving from the hospital setting to the outpatient facility to lower costs, expedite recovery, and collect reimbursement in today’s U.S. healthcare climate.

Artificial Blood Vessels Market Regional Insights

Geographically, North America contributed the largest share to the artificial blood vessels market in 2024, which was mainly attributed to the well-established healthcare industry, the high incidence of cardiovascular disorders, and a huge presence of market players.

The U.S. artificial blood vessels market size was valued at USD 0.67 billion in 2024 and is expected to reach USD 0.89 billion by 2032, growing at a CAGR of 3.76% over 2025-2032. The US is the largest contributor with increasing demand for vascular grafts in CABG and dialysis procedures, which perform over 400,000 bypass surgeries every year. Strong R&D investment (NIH funded USD 2.4bn in CVD research in 2023), alongside a positive regulatory environment by the FDA to drive the market adoption. Canada is also advancing on the back of increased adoption of 3D-printed vascular models in academia. Mexico is heading forward with rolling reforms,  better public health campaigns, and international collaboration in clinical trials.

Europe is the second-highest growing and second-largest regional market, and is driven by the rising occurrence of vascular diseases, government initiation of various innovation programs, and advanced surgical techniques. Among others, the presence of companies such as Jotec GmbH, a high volume of procedures, and an advanced healthcare system, Germany is at the forefront in the regional market.

The UK and France are also expanding, in no small part because the NHS is funding novel vascular trials. In addition, European nations have various CE mark certifications to expedite product approvals and adoption. There is an increasing demand for healthcare in Italy and Spain owing to a higher incidence of chronic disease and an aging population.

The artificial blood vessels market in Asia Pacific is the fastest growing due to rapid modernization in healthcare, high patient population, and increasing prevalence of chronic diseases. China leads the way in space, including the recent news that BioDAS received the country’s first NMPA approval for an artificial blood vessel. It is also heavily pursuing 3D bioprinting technologies for vascular reconstruction.

India is experiencing a thriving market, backed up by its increasing dialysis population (estimated to surpass 0.5 million ESRD patients by 2030) and burgeoning public and private investments in healthcare. Japan continues to be one of the centres of biomaterial research and surgical innovation, and South Korea and Australia are pouring more and more of their investment into regenerative medicine.

Key Players in the Artificial Blood Vessels Market

Leading artificial blood vessels companies operating in the market are Braun Melsungen, Becton Dickinson, Cook Medical, Medtronic, LeMaitre Vascular, Terumo Medical, W. L. Gore & Associates, Jotec GmbH, Humacyte Inc., and Techshot Inc.

Recent Developments in the Artificial Blood Vessels Market

• In April 2025, A group of researchers and physicians submitted a formal petition urging the FDA to expedite review processes for artificial blood vessels used in critical trauma care, citing rising clinical demand and recent battlefield applications.

• In March 2025, Humacyte’s lab-grown blood vessel gained national attention after it was successfully used in emergency trauma cases; the FDA is now reviewing it under an emergency use framework amid mounting pressure from trauma surgeons.